Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Nanotech Guidance Takes Small Step Forward

This article was originally published in The Tan Sheet

Executive Summary

FDA initiates a dialogue with industry on nanotechnology in regulated products via a broad draft guidance document.

You may also be interested in...



In Nanotech Metrics, Safety Should Trump Size, Experts Say

Presenters at the FDLI annual conference say evaluations of novel health care and consumer products based on nanotechnology should focus on safety and efficacy more than particle size. The Project on Emerging Nanotechnologies is updating its product inventory to include nanomaterial safety data.

In Nanotech Metrics, Safety Should Trump Size, Experts Say

Presenters at the FDLI annual conference say evaluations of novel health care and consumer products based on nanotechnology should focus on safety and efficacy more than particle size. The Project on Emerging Nanotechnologies is updating its product inventory to include nanomaterial safety data.

“Nano-Free” Sunscreen Claim Spurs Environmental Group Complaint

Friends of the Earth claims that materials supplier Antaria misleads its customers and consumers by billing the ZinClear-IM sunscreen ingredient as “nano-free” when third-party testing shows it contains “clusters” of nanoparticles. The issue of defining nanotechnology continues to be debated internationally.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS105108

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel